Citations

Clear

1134 citation(s) found for "Su, Yan".

Revolutionizing nephrocalcinosis treatment: IL ‐10 engineered macrophages as a novel therapeutic approach
Zhao, Wenlei , Wang, Kailong, Chen, Hairui , Xu, Junnan , Wen, Lequan , Wu, Yan , Chen, Weihao , Liu, Yanzhong, Zhang, Luo , Zhang, Xu , Mai, H. , Mai, Haixing , Liu, Haitao , Liu, Yanzhong, Zhang, Jiqing , Lieske, John C.

Mayo Clinic

Bioengineering & Translational Medicine | July 11, 2025 | Volume: 11 | Issue: 1 | Pages: No page available

10.1002/btm2.70047 | PMID 41573378 Get It

Abstract Nephrocalcinosis provides a nidus for stone formation and is strongly linked to renal injury and chronic kidney disease. Although the crucial role of macrophages in the formation and progression of calcium oxalate (CaOx) crystals has long been widely recognized, finding effective immunotherapies for nephrocalcinosis remains a challenge. In this study, we described an innovative macrophage‐based method that delivers interleukin‐10 (IL‐10) into the kidney, reduces the deposition of CaOx crystals, and alleviates renal injury in a mouse model of glyoxylate‐induced CaOx. Compared with recombinant IL‐10 direct injection, the macrophage‐based method has the advantages of biocompatibility and sustaining action. We found that the transplantation of engineered macrophages via the tail vein significantly reduced the volume of crystals in the kidney, thereby alleviating the kidney injury caused by crystal. In mechanistic studies, IL‐10‐secreting macrophages inhibited crystal formation and promoted crystal clearance by promoting macrophage M2 polarization, exerting a protective effect on renal tissue. Our data suggest that macrophage‐based delivery of IL‐10 to the kidney can be a potential treatment method for nephrocalcinosis.
Lifetime Risk of First Symptomatic ICH or Seizure in Familial Cerebral Cavernous Malformations
Dammann, Philipp , Santos, Alejandro N. , Mavarani, Laven , Chabriat, Hugues , Croft, Jacob , Renteria, Mellisa, Jang, David, Zhang, Jun , Li, Da , Weng, Jiancong , Pilz, Robin A. , Felbor, Ute , Steinberg, Gary K. , Bervini, David , Raabe, Andreas , Rosales, Julieta , Rieß, Christoph , Karadachi, Hannah, Li, Yan , Köhrmann, Martin, Frank, Benedikt , Schmidt, Börge , Overstijns, Manou , Fung, Christian , Zafar, Atif , Nelson, Jeffrey , Zabramski, Joseph M. , Akers, Amy , Kim, Helen , Guey, Stéphanie , Chabriat, Hugues , Herve, Dominique , Zhang, Jun , Weng, Jian-Cong , Rath, Matthias , Steinberg, Gary K , Bervini, David , Rauschenbach, Laurèl , Jabbarli, Ramazan , Beck, Jürgen , Fung, Christian , Al-Shahi Salman, Rustam , Flemming, Kelly D , Lanzino, Giuseppe , Morrison, Leslie , Kim, Helen , Sure, Ulrich , Karadachi, Hanah Hadice , Santos, Alejandro N. , Guey, Stéphanie , Wu, Zhenhua , Petracca, Antonio , Fusco, Carmela , D’Agruma, Leonardo , Castori, Marco , Gu, Jing , Goldberg, Johannes , Cervio, Andrés , Villamil, Facundo , Rauschenbach, Laurèl , Oppong, Marvin Darkwah , Ahmadipour, Yahya , Wrede, Karsten Henning , Jabbarli, Ramazan , Deuschl, Cornelius , Piedade, Guilherme Santos , Wälchli, Thomas , Salman, Rustam Al‐Shahi , Flemming, Kelly D. , Lanzino, Giuseppe , Weinsheimer, Shantel , McCulloch, Charles E. , Sure, Ulrich

Mayo Clinic

Neurology | July 10, 2025 | Volume: 105 | Issue: 3 | Pages: No page available

10.1212/wnl.0000000000213798 | PMID 40638881 Get It

Development of a Hepatocyte‐Specific Temporal Genetic Mouse Model Using Albumin Promoter‐Driven FlpER2 Expression
Wang, Bin , Wang, Jiale , Liu, Yang , He, Gordon, Jahan‐mihan, Yasmin , Hu, Jie , Li, Audrey , Bi, Yan , Ji, Baoan , Wang, Yuxi, Muhammad, Faheem, Wang, Jiale , Wang, Bin , He, Gordon, Wang, Di , Faheem, Muhammad

Mayo Clinic

genesis | July 9, 2025 | Volume: 63 | Issue: 4 | Pages: No page available

10.1002/dvg.70022 | PMID 40631533 Get It

ABSTRACTTissue‐specific gene manipulation using Cre/loxP or Flp/frt recombination systems is a cornerstone of genetically engineered mouse models. In this study, we aim to develop a novel hepatocyte‐specific, tamoxifen‐inducible Flp mouse line. BAC (bacterial artificial chromosome)‐Alb(albumin)‐FlpER2(estrogen receptor ligan binding domain) was developed by inserting IRES‐FlpER2 cDNA between the translation stop codon and 3′‐UTR of the mouse albumin gene in a bacterial artificial chromosome. Upon tamoxifen induction in mice crossed with reporter lines, western blotting, immunohistochemistry, immunofluorescence staining, and X‐gal staining (5‐bromo‐4‐chloro‐3‐indolyl‐β‐D‐galactopyranoside Staining) were used to verify the recombination efficiency and specificity of this mouse model. Recombination was highly efficient and specific in hepatocytes, with no recombination detected in intrahepatic cholangiocytes or other organs in this mouse model. We generated a new tamoxifen‐induced hepatocyte‐specific mouse model with highly efficient recombination specifically in hepatocytes, and this model can be used to generate tumor model lines.
AncestryGeni: a novel genetic ancestry classification pipeline for small and noisy sequence data
Elhaik, Eran , Behnamian, Sara , Howe, M. S., Tang, Hongwei , Yan, Huihuang , Tian, Shulan , Shivaram, Suganti, Mendoza, Cinthya Zepeda, Blaney, Patrick , Howe, Michael, Zepeda Mendoza, Cinthya, Maura, Francesco , Baughn, Linda B , Elhaik, Eran , Tian, Shulan , Blaney, Patrick , Howe, Michael, Zepeda‐Mendoza, Cinthya , Maclachlan, Kylee , Usmani, Saad Z. , Pirooznia, Mehdi , Morgan, Gareth J. , Maura, Francesco , Baughn, Linda B.

Mayo Clinic

Bioinformatics | July 8, 2025 | Volume: 41 | Issue: 7 | Pages: No page available

10.1093/bioinformatics/btaf391 | PMID 40627371 Get It

Abstract Motivation Efforts to address health disparities are often limited by the lack of robust computational tools for inferring genetic ancestry by calculating an individual’s genetic similarity to continental groups. We have already shown that a preferred alternative to self-described race is using ancestry-informative markers (AIMs) that can be classified into ancestral components and used to estimate their similarity to those of known populations to identify continental groups. However, real-world genomic data can present challenges, including limited availability of germline DNA, a small number of AIMs for each sample, and the use of different variant calling software, limiting the application of existing solutions. Results Here, we describe a novel supervised machine-learning tool AncestryGeni, which infers genetic ancestry for samples with even a hundred markers and is applicable to any genomic data, including whole exome sequencing (WES) and RNA sequencing (RNA-Seq) data. Applying AncestryGeni to a real-world genomic dataset obtained from the Multiple Myeloma Research Foundation (MMRF) CoMMpass study, we show that it is more accurate than the commonly used FastNGSadmix when using nonstandard genomic material. We also demonstrate that when using AncestryGeni, the tumor-derived sequence obtained from WES and RNA-Seq can be a robust data source to accurately estimate an individual’s genetic similarity to a continental group. Availability and implementation AncestryGeni pipeline is available at https://github.com/eelhaik/AncestryGeni/tree/main.
DNA2 protein destruction dictates DNA hyperexcision, cGAS–STING activation, and innate immune response in CDK12-deregulated cancers
Peng, Jiang , Wang, Zhijun , Yan, Binyuan , Zhu, Shouhai , Huang, Zhenlin , Zhang, Jianong , Ding, Donglin , Li, Xiang , Wang, Liguo , Jin, Baiye , Pang, Jun, Xia, Dan , Sun, Rui , Yan, Binyuan , Zhu, Shouhai , Wang, Liguo , Lou, Zhenkun , Jin, Baiye , Huang, Rui , Sun, Rui , Wang, Zhijun, Lou, Zhenkun , Jin, Baiye , Pang, Jun , Huang, Haojie , Sun, Rui

Mayo Clinic

Proceedings of the National Academy of Sciences | July 7, 2025 | Volume: 122 | Issue: 28 | Pages: No page available

10.1073/pnas.2413732122 | PMID 40623188 Get It

CDK12 primarily functions as a transcription regulatory cyclin-dependent kinase (CDK) that controls mRNA elongation, splicing, and polyadenylation. The CDK12 gene is implicated in human cancers since it is frequently mutated and/or deleted in prostate and ovarian cancer but paradoxically amplified in breast cancer. Here, we demonstrate that CDK12 promotes serine-933 phosphorylation of DNA2, a nuclease/helicase critical for replication fork stress regulation, and the phosphorylation subsequently facilitates DNA2 polyubiquitination and degradation mediated by the APC/C CDC20 E3 ubiquitin ligase. CDK12 inactivation induces but amplification suppresses genome-wide expression of interferon response and antigen processing and presentation machinery genes in ovarian and breast cancer cells, respectively. Besides causing aberrant DNA2 stabilization, replication stress, genomic instability, and cytosolic double-stranded DNA (dsDNA) accumulation, CDK12 loss also triggers cGAS–STING activation and innate immune response, which can be reversed by forced expression of replication protein A (RPA) subunits or DNA2 depletion. Our findings identify DNA2 as a phosphorylation substrate of CDK12, connecting CDK12 to cell cycle regulation. These data also reveal DNA2 protein destruction as a critical mechanism that dictates genomic instability, cGAS–STING signaling activation, and innate immune response in CDK12-deregulated cancers.
Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma
Breen, William G. , Anderson, S. Keith , Brown, Paul D. , Yan, Elizabeth , Kizilbash, Sani H. , Anderson, Daniel M. , Tran, David , Mazurczak, Miroslaw, Geoffroy, Francois J., Leinweber, Clinton, Dixon, Jesse G. , Anderson, S Keith , Yan, Elizabeth S, Kizilbash, Sani, Galanis, Eva, Kizilbash, Sani H , Sarkaria, Jann N. , Galanis, Evanthia , Tran, David D. , Johnson, Derek R. , Laack, Nadia N.

Mayo Clinic

Neuro-Oncology | June 27, 2025 | Volume: 27 | Issue: 10 | Pages: 2661-2670

10.1093/neuonc/noaf156 | PMID 40579995 Get It

Abstract Background Dasatinib is an oral inhibitor of the Src kinase family, with preclinical data indicating impact on gliomagenesis, tumor invasion, and radiosensitivity. Methods North Central Cancer Treatment Group N0877 is a phase 1 dose escalation and phase II randomized study evaluating the maximum tolerated dose (MTD), safety, and efficacy of dasatinib with radiation and temozolomide (TMZ) for glioblastoma. Following identification of the MTD, adult patients with a histologic diagnosis of glioblastoma were randomized 2:1 between dasatinib given with standard concurrent and adjuvant TMZ, versus placebo with standard concurrent and adjuvant TMZ. Radiation dose was 60 Gy in 30 fractions. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), toxicity, and quality of life. Results Thirteen patients were enrolled in the phase I component and established the MTD and phase II dose of 150 mg given daily. A total of 204 patients were enrolled in the phase II component. OS was not different between arms (median OS 15.6 months for dasatinib compared to 19.3 months for placebo, hazard ratio:1.21 favoring placebo, 95% CI: 0.88–1.65, log-rank P-value: .238). Similarly, PFS was not significantly different between the dasatinib and placebo arms. There was a significant increase in anemia, nausea, and creatinine elevation with dasatinib, but significantly more grade 3 lymphopenia with placebo. Conclusions The addition of dasatinib to standard chemoradiation did not improve outcomes for patients with glioblastoma. Clinical Trial Identifier NCT00869401.
Autoimmune Inner Ear Disease from a Rheumatologic Perspective
Diaz‐Menindez, Maximiliano , Chindris, Ana‐Maria , Mead‐Harvey, Carolyn , Li, Yan , Butendieck, Ronald R., Chirilă, Răzvan M. , Britt, Katherine L., Berianu, Florentina , Chindris, Ana-Maria , Britt, Katherine L.

Mayo Clinic

Diagnostics | June 23, 2025 | Volume: 15 | Issue: 13 | Pages: 1577

10.3390/diagnostics15131577 | PMID 40647576 Get It

Background/Objectives: Autoimmune inner ear disease (AIED) causes sensorineural hearing loss that classically presents as fluctuating, asymmetric loss of hearing. Associated vestibular and other ear symptoms can be present in many patients. First-line treatment of AIED is high-dose corticosteroids. AIED can present either as a primary condition limited to ear involvement or secondary, as part of an underlying systemic autoimmune rheumatic disease, the most common of which include vasculitis and relapsing polychondritis. We described our cohort of primary AIED, including demographics, treatment, and outcomes. We excluded from this review sensorineural hearing loss in the context of vasculitis and relapsing polychondritis. Methods: We performed a chart review of patients with the diagnosis of AIED at Mayo Clinic and compared the cohort by sex. Results: Thirty-one patients met the inclusion criteria. The mean age was 48.5 years, and 17 were men. Patients were initially evaluated at the Department of Otorhinolaryngology or Internal Medicine, and 29 patients were subsequently referred to the Department of Rheumatology, with a mean of 12.2 weeks after the first evaluation. Treatment with corticosteroids showed improvement in hearing and vestibular symptoms during the first month but no further improvement by the end of the third month. Other immunosuppressive medications were used with various degrees of response. Methotrexate was the second most used therapy, with 11 of 17 patients reporting an improvement in symptoms. Conclusions: Corticosteroid therapy is an effective initial treatment for AIED and should be followed with corticosteroid-sparing agents to prevent further damage to the cochlea.
549 | PROSPECTIVE PATIENT PREFERENCE STUDY FOR CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT ATTRIBUTES IMPACTING PATIENT SHARED‐DECISION MAKING
Challagulla, Swetha, Pilon, Dominic , Meng, Yan , Díaz, Lilián , Ailawadhi, Sikander , Totev, Todor , Meng, Y., Diaz, L., Chen, Zhiguo , Yang, Kehu

Mayo Clinic

Hematological Oncology | June 15, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70096_549 Get It

Computer‐aided detection for esophageal achalasia (with video)
Shiwaku, Hironari , Misawa, Masashi , Inoue, Haruhiro , Boškoski, Ivo , Shimamura, Yuto , Ikebuchi, Yuichiro , Ominami, Masaki , Htet, Hein , Messmann, H, Colosso, Bianca Maria Quarta , Repici, Alessandro , Stavropoulos, Stavros N. , Bechara, Robert , Sethi, Amrita, Beyna, Torsten , Santi, Esperanza Grace , Sharma, Prateek , Eleftheriadis, Nikolas, Minami, Hitomi, Haber, Gregory , Seewald, Stefan , Shiwaku, Akio, Shiwaku, Yoshiyuki, Mori, Kensaku, Costamagna, Guido , Shimamura, Yuto , Ikebuchi, Yuichiro , Iwaya, Yugo , Htet, Hein Myat Thu , Colosso, Bianca Maria Quarta , Bechara, Robert , Kahaleh, Michel , Beyna, Torsten , Jiang, Kai, Oda, Masahiro , Familiari, Pietro , Hayee, Bu , Ho, Khek Yu , So, Jimmy Bok Yan , Bhandari, Pradeep , Grimes, Kevin L. , Maselli, Roberta , Hassan, Cesare , Fukami, Norio , Kahaleh, Michel , Sethi, Amrita , Neuhaus, Horst Ekkehard , Chiu, Philip Wai Yan , Eleftheriadis, Nikolas, Draganov, Peter V. , Mori, Kensaku , Kudo, Shin‐ei , Hasegawa, Suguru

Mayo Clinic

Digestive Endoscopy | June 12, 2025 | Volume: 37 | Issue: 8 | Pages: 851-861

10.1111/den.15028 | PMID 40506418 Get It

ObjectivesAchalasia is an esophageal motility disorder that impairs quality of life and is often missed (20–50%) on endoscopy. A newly developed computer‐aided detection (CAD) software has shown high accuracy for achalasia diagnosis in preclinical settings. However, its benefit in a clinical setting remains unclear.MethodsBetween February and August 2023, 83 endoscopists from 27 centers assessed 50 randomized endoscopic videos (25 achalasia, 25 nonachalasia) without and with CAD. Endoscopists assessed videos without CAD, then with CAD after 2 months. The primary end‐point was improvement in sensitivity for nonexperienced endoscopists (no endoscopic experience of achalasia). Sensitivity, specificity, and accuracy with and without CAD were compared using the McNemar test.ResultsSensitivity for diagnosing achalasia increased significantly with CAD, rising from 74.2% (95% confidence interval [CI] 72.2–76.0%) to 91.2% (95% CI 89.9–92.4%) for all readers, showing a difference of 17.1% (95% CI 15.1–19.0%). Specifically, sensitivity improved from 66.9% (95% CI 63.6–70.0%) to 91.9% (95% CI 89.9–93.6%) among nonexperienced endoscopists, resulting in a difference of 25.0% (95% CI 21.7–28.4%), and from 79.5% (95% CI 77.1–81.8%) to 90.8% (95% CI 89.0–92.3%) among experienced endoscopists (endoscopic experience of at least one achalasia case), with a difference of 11.3% (95% CI 8.9–13.6%). Accuracy and specificity improved significantly with CAD assistance, regardless of reader's experience.ConclusionCAD improves achalasia detection by 17%, confirming preclinical results. The benefit was higher for nonexperienced endoscopists. CAD assistance may lead to prompt and effective treatment, minimizing the risk of false‐negative diagnosis in clinical practice.Trial registrationThis study was registered in the University Hospital Medical Information Network Clinical Trial Registry (https://www.umin.ac.jp/ctr/) number: UMIN000053047.